Prescription drug · ANDA
Irinotecan hydrochloide NDC 70700-169
Irinotecan hydrochloride 20 mg/mL · Injection · Intravenous · Xiromed LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70700-169-22 | 70700016922 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70700-169-22) / 2 mL in 1 VIAL, SINGLE-DOSEMarketed from Nov 18, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Irinotecan hydrochloide
- Generic name (nonproprietary)
- irinotecan hydrochloide
- Active ingredients
- Irinotecan hydrochloride — 20 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Xiromed LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 212993
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 70700-169_4b364426-00fb-0ef1-e063-6394a90aaba6SPL ID 4b364426-00fb-0ef1-e063-6394a90aaba6SPL set ID b26e5d27-dba5-7538-9e7b-48b358998cbbRxCUI 1726319, 1726324UNII 042LAQ1IISUPC 0370700170229, 0370700169223
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470700016922followed by a unit qualifier and the quantityPackage 70700-0169-22. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. ( 1 ) Patients with metastatic carcinoma of the colon or rectum whose disease has …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 212993
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-027 |
| Irinotecan hydrochloide | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | BluePoint Laboratories | 68001-480 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-131 |
| Irinotecan hydrochloide | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Gland Pharma Limited | 68083-381 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Gland Pharma Limited | 68083-382 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Xiromed LLC | 70700-170 |